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ABSTRACT
Objective Deﬁne the real-world performance of recently
updated National Institute for Health and Care Excellence
guidelines (TA314) on implantable cardioverter-deﬁbrillator
(ICD) use in people with chronic heart failure.
Methods Multicentre prospective cohort study of 1026
patients with stable chronic heart failure, associated with
left ventricular ejection fraction (LVEF) ≤45% recruited in
cardiology outpatient departments of four UK hospitals.
We assessed the capacity of TA314 to identify patients at
increased risk of sudden cardiac death (SCD) or
appropriate ICD shock.
Results The overall risk of SCD or appropriate ICD shock
was 2.1 events per 100 patient-years (95% CI 1.7 to
2.6). Patients meeting TA314 ICD criteria (31.1%) were
2.5-fold (95% CI 1.6 to 3.9) more likely to suffer SCD or
appropriate ICD shock; they were also 1.5-fold (95% CI
1.1 to 2.2) more likely to die from non-cardiovascular
causes and 1.6-fold (95% CI 1.1 to 2.3) more likely to
die from progressive heart failure. Patients with diabetes
not meeting TA314 criteria experienced comparable
absolute risk of SCD or appropriate ICD shock to patients
without diabetes who met TA314 criteria. Patients with
ischaemic cardiomyopathy not meeting TA314 criteria
experienced comparable absolute risk of SCD or
appropriate ICD shock to patients with non-ischaemic
cardiomyopathy who met TA314 criteria.
Conclusions TA314 can identify patients with reduced
LVEF who are at increased relative risk of sudden death.
Clinicians should also consider clinical context and the
absolute risk of SCD when advising patients about the
potential risks and beneﬁts of ICD therapy.
INTRODUCTION
Reduced left ventricular ejection fraction (LVEF)
secondary to myocardial infarction is well estab-
lished as a major risk factor for sudden cardiac
death (SCD) due to ventricular arrhythmia.1 This
observation led to a number of clinical trials exam-
ining the effect of prophylactic implantable
cardioverter-deﬁbrillators (ICDs) in patients with
reduced LVEF due to myocardial infarction.2–5
These trials were followed by studies addressing the
same question in patients with reduced LVEF asso-
ciated with heart failure due to ischaemic and non-
ischaemic aetiologies.5 6
Multiple guidelines now recommend the implant-
ation of ICD as primary prevention in patients with
reduced LVEF. The resultant widespread
prophylactic implantation of ICD presents an
important challenge to healthcare systems as these
devices are expensive,7 and when implanted,8 or
activated inappropriately,9 are associated with an
increased risk of harm to patients. Moreover, some
studies of patients at high-risk of SCD (eg, within 1–
6 weeks after myocardial infarction) have failed to
demonstrate a survival advantage from ICD.10 11
ICD use should, therefore, be targeted towards
groups of patients most likely to receive clinically
meaningful beneﬁt from this treatment.12 Indeed,
post hoc analysis of the multicenter automatic deﬁb-
rillator implantation trial (MADIT)-II study has sug-
gested ICD implantation was not associated with
beneﬁt in patients at the highest and lowest risk of
death, based upon a simple clinical risk score.13
The updated UK National Institute for Health
and Care Excellence (NICE) technology appraisal
(TA314) guidance on device therapy for patients
with reduced left ventricular systolic function was
published in 2014.14 These guidelines, which rep-
resent a signiﬁcant change in UK practice, stratify
patients suitable for ICD using New York Heart
Association (NYHA) functional class and QRS
interval duration from 12-lead ECG. The ability of
these guidelines to identify patients at increased
risk of SCD has not been examined. In the present
report, we used a prospectively recruited unselected
cohort of UK patients with heart failure and
reduced LVEF to examine the ability of these guide-
lines to identify patients at increased risk of SCD
and test the performance of TA314.
METHODS
This was a multicentre prospective cohort study
speciﬁcally designed to examine predictors of all-
cause mortality and mode of death in patients with
heart failure secondary to left ventricular systolic
dysfunction.15 A total of 1091 patients were
recruited between June 2006 and December 2011.
All patients were recruited in outpatient clinics
located in UK National Health Service hospitals
and provided written consent to participate in the
study. The study was approved by Leeds West
Research Ethics Committee (07/Q1205/17) and
conducted in accordance with the principles of the
Declaration of Helsinki.
Eligibility criteria
Stable (no change in clinical status during the previ-
ous 3 months) patients over the age of 18 years
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with signs and symptoms of heart failure and an echocardio-
graphic LVEF of ≤45% were recruited.
Data collection
At the time of recruitment, a patient case record form detailing
clinical and demographic data was completed. The presence of
diabetes was deﬁned on the basis of current medication and
history taken by recruiting physician. Ischaemic aetiology was
determined by the recruiting physician on the basis of detailed
history, ECG and clinically indicated imaging, including coron-
ary angiography.15 Furosemide dose equivalent was calculated
using the ratio 1 mg bumetanide equivalent to 40 mg furosem-
ide. Ramipril and bisoprolol equivalent doses were derived
according to our previously published work.15 16 NYHA class
was deﬁned using standard criteria.15 A blood sample was taken
for electrolytes, urea, creatinine, liver function and random
glucose. Estimated glomerular ﬁltration rate was calculated using
the modiﬁcation of diet in renal disease method.17 A 2-
dimensional echocardiogram was performed and reported by
British Society of Echocardiography (BSE) accredited cardiac
physiologists according to BSE guidelines.18 A standard 12-lead
ECG was performed at the time of recruitment.
ECG analysis
Standard 12-lead ECGs recorded at 25 mm/s were analysed
by two cardiologists blinded to patient characteristics (RMC
and AR).
Application of NICE TA314
All patients with LVEF ≤35%, NYHA class I–III symptoms and
QRS duration ≥120 ms were deemed to meet NICE recommen-
dations for ICD implantation (labelled ‘standard TA314’). As
TA314 does not clearly stipulate how to deﬁne high-risk patients
with QRS duration <120 ms, we conducted sensitivity analyses
where all patients with LVEF ≤35%, NYHA class I–III symp-
toms, irrespective of QRS duration, were deemed to meet
TA314 criteria (labelled ‘extended TA314’). Patients with per-
manent pacemakers and no intrinsic QRS interval (n=45) were
excluded from analyses, as TA314 offers no guidance on their
risk stratiﬁcation. Patients with missing NYHA class, ECG or
echocardiogram data (n=20) were also excluded from analyses,
resulting in a study cohort of 1026 patients.
Mode of death and assessment of ICD shocks
All patients were registered with the UK Ofﬁce of Population
Censuses and Surveys (ONS) to provide details of death includ-
ing date and location. Mode of death was assessed as previously
reported and as follows:15 16 (1) sudden death if occurring
within 1 h of a change in symptoms or during sleep or while
the patient was unobserved or appropriate ICD shock, (2) pro-
gressive heart failure if death occurred after a documented
period of symptomatic or haemodynamic deterioration, (3)
other cardiovascular death if not occurring suddenly or in asso-
ciation with progression of heart failure and (4) non-
cardiovascular death. For patients with an ICD in situ an appro-
priate shock was classed as a sudden death event. Each patient
with an ICD has a ﬁle detailing information at follow-up con-
taining information describing therapies including a copy of
ECGs from the device diagnostics of individual episodes.
Detection algorithms and therapy settings at the time of therapy
are also recorded. Analysis of each episode of device therapy
was undertaken by a British Heart Rhythm Society-accredited
cardiac physiologist ( JG) to assign whether or not therapy was
appropriate or inappropriate as previously described.9
Statistics
Descriptive group data are given as mean with SEM. Categorical
data are shown as number (%). All analyses were performed
using SPSS V.21.0 (IBM, New York, USA). Groups were com-
pared using Student’s t test for continuous data and Pearson’s χ2
for categorical data, using two-sided tests. Survival was com-
pared with log-rank tests. Cox proportional hazards regression
analysis was used to deﬁne associations between clinical vari-
ables and risk of SCD, which are presented as HR. Absolute
event rates are provided per 100 patient-years (100 py) of
follow-up, with accompanying 95% CIs in parentheses.
Statistical signiﬁcance was accepted at p<0.05.
RESULTS
Patient characteristics and mortality
A total of 1026 patients were recruited (characteristics shown in
table 1) between June 2006 and December 2011, with mean
follow-up of 1360 days (SEM 21), equating to 3823 patient-
years of follow-up. The mean age of the cohort was 68 years,
and 73.6% were men; 25.7% suffered from diabetes and 63.1%
had an underlying ischaemic aetiology. QRS duration ≥120 ms
was present in 46.6% (29.4% left bundle branch block (LBBB)
morphology, 5.6% right bundle branch block (RBBB) morph-
ology, 11.6% non-speciﬁc morphology). Heart failure therapies
were used as follows: β-adrenoceptor antagonists in 81%, ACE
inhibitors or angiotensin receptor blockers in 89%, mineralocor-
ticoid receptor antagonists in 41%, cardiac resynchronisation
therapy in 29% and ICD in 13%. More speciﬁcally, 69.2% of
patients had no device, 3.3% had ICD alone, 18.3% had
cardiac resynchronisation therapy pacemaker (CRT-P) and 9.2%
had cardiac resynchronisation therapy deﬁbrillator
(CTR-D). All-cause mortality rate was 9 (8.1–10) events/100 py,
and SCD rate was 2.1 (1.7–2.6) events/100 py. Of 344 total
mortality events, 22.7% were attributable to SCD, 32% to pro-
gressive heart failure death, 7.3% to other cardiovascular death,
34.9% to non-cardiovascular death and 3.2% were unclassiﬁ-
able. Of the 78 SCD events, 28 were appropriate ICD shocks (8
ventricular ﬁbrillation and 20 ventricular tachycardia), with a
median programmed threshold for ICD shock of 188 bpm
(range 188–240).
Performance of NICE TA314 guidelines
31.1% of patients fulﬁlled NICE standard TA314 criteria for
ICD implantation. In addition to expected differences in NYHA
class and QRS interval, patients recommended to receive ICD
were older, had more impaired ventricular systolic function, less
often had diabetes, and were much more likely to receive
cardiac resynchronisation therapy (table 1). Patients fulﬁlling
TA314 criteria were more likely to die from any cause (HR 1.5
(1.2 to 1.9); p<0.001; ﬁgure 1A), from SCD (HR 2.5 (1.6 to
3.9); p<0.001; ﬁgure 1B), from progressive heart failure (HR
1.6 (1.1 to 2.3); p=0.02) and from non-cardiovascular causes
(HR 1.5 (1.1 to 2.2); p=0.027) than those not fulﬁlling TA314
criteria.
Guideline performance according to clinical context
Univariate predictors of SCD were sought to deﬁne clinical
contexts where guideline performance may vary (table 2). This
indicated that diabetes and ischaemic aetiology are also import-
ant predictors of risk, and these observations persisted in a
multivariate analysis including diabetes, ischaemic aetiology and
NICE TA314 status (table 3). Moreover, there was no inter-
action between TA314 and diabetes or ischaemic aetiology,
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indicating a similarly adverse impact of these comorbidities
independent of TA314 status. Furthermore, study recruitment
era (ﬁrst vs second half of study recruits) did not interact with
TA314, suggesting no change in performance over time. We
then produced Kaplan–Meier curves of SCD risk in patients
with or without diabetes (ﬁgure 2A) or ischaemic aetiology
(ﬁgure 2B), according to NICE TA314 recommendation status.
These clearly illustrate that although the guidelines deﬁne
groups with increased relative risk, the absolute risk of SCD
remains highly inﬂuenced by clinical context. For example,
event rates in patients with diabetes not meeting TA314 criteria
were similar to patients without diabetes who met TA314
criteria.
Sensitivity analyses
TA314 supports the provision of ICDs to patients with QRS
duration <120 ms who are deemed to be at high risk of SCD,
although provides no speciﬁc guidance regarding how to make
this assessment. We, therefore, conducted a sensitivity analysis
of extended TA314 criteria, in which ICD candidacy required
only LVEF ≤35% and NYHA class I–III symptoms (59.6% of
patients). Patients meeting extended TA314 criteria were no
longer at increased risk of all-cause mortality (HR 1.2 (1.0 to
1.5); p=0.13), but remained at greater risk of SCD (HR 2.0
(1.2 to 3.4); p=0.007). In multivariate analysis identical to that
presented in table 3, extended TA314 criteria, diabetes and
ischaemic aetiology all remained independently associated with
the risk of SCD. The impact of diabetes or ischaemic aetiology
on extended TA314 criteria performance is further illustrated in
ﬁgure 3, reproducing our observations regarding standard
TA314 criteria in ﬁgure 2.
As patients with current device therapy may experience a dif-
ferential risk of SCD, we also conducted a sensitivity analysis of
standard TA314 criteria performance by excluding all patients
with device therapy (n=316). In this scenario, TA314 was asso-
ciated with risk of all-cause mortality (HR 2.3 (1.7 to 3.0);
p<0.001) and risk of SCD (HR 3.9 (2.0 to 7.6); p<0.001).
In multivariate analysis identical to that presented in table 3,
standard TA314 criteria, diabetes and ischaemic aetiology all
remained independently associated with the risk of SCD. The
impact of diabetes or ischaemic aetiology on standard TA314
criteria performance is further illustrated in ﬁgure 4, reprodu-
cing our observations regarding standard TA314 criteria in
ﬁgure 2.
DISCUSSION
This study of >1000 patients with heart failure examines the
ability of the NICE TA314 guidelines to identify patients at risk
of SCD. The most important ﬁndings are as follows: (1)
between 30% and 60% of unselected patients with heart failure
are now eligible to receive an ICD, depending on the attribution
of high-risk status to patients with narrow QRS interval; (2)
overall risk of SCD in patients with heart failure due to reduced
LVEF is approximately 2% per annum, making risk stratiﬁcation
for ICD implantation a clinical priority; (3) patients fulﬁlling
the TA314 criteria for ICD implantation are at increased risk of
SCD, compared with those not fulﬁlling the criteria and (4) the
performance of TA314 in deﬁning high absolute risk of SCD is
signiﬁcantly inﬂuenced by clinical context. This means that
some patient subgroups meeting TA314 criteria for ICD
implantation experience similar absolute risk of SCD to other
subgroups that do not meet TA314 criteria for ICD
implantation.
The use of ICD in patients with heart failure due to reduced
LVEF is now a mainstay of treatment worldwide with >5000
devices implanted in the UK during 2012, a rise of >10% from
Table 1 Cohort characteristics
TA314 does not
advise ICD (n=707)
TA314 advises
ICD (n=319) p Value
Age (years) 669 (5) 706 (6) <0.001
Heart rate (bpm) 75 (8) 742 (1) 0.52
Systolic blood pressure (BP) (mm Hg) 123 (8) 1168 (12) <0.001
QRS interval (ms) 1106 (1) 1522 (13) <0.001
Haemoglobin (g/l) 136 (1) 135 (1) 0.38
eGFR (mL/kg/1.73 m2) 562 (7) 532 (9) 0.008
LVEDD (mm) 562 (3) 629 (5) <0.001
LVEF (%) 347 (3) 263 (4) <0.001
Ramipril dose (mg/day) 5 (1) 49 (2) 0.73
Bisoprolol dose (mg/day) 38 (1) 33 (2) 0.038
Furosemide dose (mg/day) 516 (19) 574 (29) 0.094
Diabetes (% (n)) 286 (202) 197 (63) 0.003
Ischaemic aetiology (% (n)) 636 (450) 599 (191) 0.25
CRT (% (n)) 146 (103) 564 (180) <0.001
ICD (% (n)) 92 (65) 235 (75) <0.001
NYHA class (% (n)) <0.001
I 228 (161) 166 (53)
II 484 (342) 411 (131)
III 264 (187) 423 (135)
IV 24 (17) 0
ACEi/ARB use (% (n)) 882 (623) 886 (280) 0.87
β-blocker use (% (n)) 82 (579) 797 (252) 0.39
MRA use (% (n)) 388 (274) 475 (150) 0.009
ARB, angiotensin receptor blocker; CRT, cardiac resynchronisation therapy; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator; LVEDD, left ventricular
end diastolic dimension; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
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2009.19 These devices are well tolerated and, after initial con-
cerns, it has been shown that after implantation patients do not
suffer from deterioration in their quality of life.20 Guidelines
from the American Heart Association, American College of
Cardiologists and the Heart Rhythm Society recommend ICD
therapy for patients with LVEF ≤35% due to myocardial infarc-
tion who are at least 40 days postmyocardial infarction and are
in NYHA functional class II or III, or in patients who have an
EF ≤30% and are in NYHA class I.21 The European Society of
Cardiology guidelines state that patients should receive an ICD
if in NYHA class II–III with an LVEF ≤35% in spite of
3 months of optimal pharmacological therapy and expected to
survive for 1 year with good functional status.22
The UK NICE guidelines in 2006 recommended ICD implant-
ation in patients who had sustained an myocardial infarction
(MI) at least 40 days previously with an LVEF ≤30% with QRS
duration on 12-lead ECG ≥120 ms.23 It was also advised that
patients with an LVEF ≤35% and non-sustained ventricular
tachycardia on ambulatory ECG and a positive electrophysio-
logical test should also receive an ICD. The recently updated
NICE TA314 guidelines now base stratiﬁcation of patients with
Table 3 Multivariate predictors of SCD or appropriate ICD shock
95% CI of HR
Variable HR Low High p Value Wald
TA314 recommends ICD 2.76 1.77 4.31 <0.001 19.9
Diabetes 2.17 1.37 3.45 0.001 10.8
Ischaemic aetiology 2.43 1.39 4.26 0.002 9.7
ICD, implantable cardioverter-defibrillator; SCD, sudden cardiac death.
Figure 2 Performance of standard TA314 criteria in patients with
diabetes or ischaemic aetiology. Kaplan–Meier curves demonstrating
that within populations stratiﬁed by (A) diabetes or (B) ischaemic
aetiology, TA314 identiﬁes subgroups at increased relative risk of
sudden death or appropriate ICD shock (p<0.05 for all within stratum
comparisons of TA314). However, absolute event rates in subgroups of
patients meeting TA314 criteria were similar to those in subgroups not
meeting TA314 criteria, depending on the presence of diabetes or
ischaemic aetiology. HF, heart failure; ICD, implantable
cardioverter-deﬁbrillator; SCD, sudden cardiac death.
Figure 1 Performance of TA314 in predicting outcome. Kaplan–Meier
curves demonstrating that TA314 identiﬁes a subgroup at increased risk
of: (A) total mortality and (B) sudden cardiac death (SCD) or
appropriate implantable cardioverter-deﬁbrillator (ICD) shock (both
comparisons p<0.05).
Table 2 Univariate predictors of SCD or appropriate ICD shock
95% CI of HR
Variable HR Low High p Value Wald
Age (per year) 1.02 1 1.04 0.045 4
Male sex 1.92 1.06 3.47 0.032 4.6
LVEF (per %) 0.967 0.945 0.99 0.005 7.9
QRS interval (per ms) 1.011 1.004 1.018 0.002 9.9
eGFR (per mL/kg/1.73 m2) 0.989 0.976 1.002 0.086 2.9
Haemoglobin (per g/dL) 0.987 0.974 0.999 0.045 4
NYHA class (vs I) 0.33 3.4
II 1.7 0.89 3.24
III 1.87 0.94 3.69
IV 1.5 0.19 11.5
Ischaemic aetiology 2.68 1.55 4.64 <0.001 12.4
Diabetes 2.36 1.51 3.7 <0.001 14.1
TA314 recommends ICD 2.53 1.62 3.94 <0.001 16.8
eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator;
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association;
SCD, sudden cardiac death.
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LVEF ≤35% on QRS duration and NYHA functional class, with
ICD implantation being recommended in patients in NYHA class
I–III and QRS duration >120 ms. It is also recommended that
where patients meet LVEF and NYHA criteria, but have QRS
<120 ms, they should receive an ICD if there is high risk of
sudden death; no guidance was provided on how to identify such
patients. Importantly, the updated guidelines no longer suggest
accounting for ischaemic aetiology during the decision-making
process. This reﬂects expert evidence the guideline panel
received, stating that ‘the aetiology (ischaemic/non-ischaemic)
does not inﬂuence the effectiveness of ICD therapy’.14
Periodic updates of NICE guidelines have the potential to
maintain ‘best practice’ and improve clinical outcomes across
the UK, sometimes by advocating major changes in clinical
decision-making. These changes may also have substantial
economic and personal impact, and must carefully consider
the threshold between overtreatment and undertreatment.
Notably, following TA314 guidance would have signiﬁcantly
increased ICD use in our ‘historic’ cohort. ICD guidelines,
including TA314, have been based on evidence provided by
clinical trials, which recruit patients who are often very dif-
ferent to those presenting in routine clinical practice.24
Additional real-world data regarding the performance of
these guidelines are therefore essential, since they have the
potential to reassure healthcare providers and patients that
ICD therapy is appropriate. In the present analysis, we have
demonstrated that NICE TA314 guidelines identify a group
of patients at signiﬁcantly increased relative risk of sudden
death. However, absolute risk prediction is also crucial from
a clinical and cost-effectiveness perspective, and our data
suggest that in this regard the performance of TA314 is
highly context speciﬁc. We recognise the signiﬁcant effort
involved in formulating TA314, including the conduct of an
individual patient network meta-analysis that required access
to data from multiple industry sponsors. Some of these
important and thorough analyses have recently been pub-
lished,25 and support the notion that the beneﬁt of ICD
therapy differs between patient subgroups. We hope that
future guidelines will be able to build on these data, and our
analyses, to further reﬁne risk stratiﬁcation by considering
other SCD risk factors, and ensure calibration to contempor-
ary real-life event rates.
Study limitations
This study is a retrospective analysis, although of a prospectively
performed cohort study, and this must be borne in mind when
interpreting the results. In particular, retrospective analysis
makes it difﬁcult to predict how competing causes of death
would change if ICD usage followed TA314 guidance. A second
Figure 4 Performance of standard TA314 criteria in patients with
diabetes or ischaemic aetiology, after excluding patients with prior
device therapy. Kaplan–Meier curves demonstrating that within
populations stratiﬁed by (A) diabetes or (B) ischaemic aetiology,
TA314 identiﬁes subgroups at increased relative risk of sudden death or
appropriate ICD shock (p<0.05 for all within stratum comparisons of
TA314). However, absolute event rates in subgroups of patients
meeting TA314 criteria were similar to those in subgroups not meeting
TA314 criteria, depending on the presence of diabetes or ischaemic
aetiology. HF, heart failure; ICD, implantable cardioverter-deﬁbrillator;
SCD, sudden cardiac death.
Figure 3 Performance of extended TA314 criteria in patients with
diabetes or ischaemic aetiology. Kaplan–Meier curves demonstrating
that within populations stratiﬁed by (A) diabetes or (B) ischaemic
aetiology, TA314 identiﬁes subgroups at increased relative risk of
sudden death or appropriate ICD shock (p<0.05 for all within stratum
comparisons of TA314). However, absolute event rates in subgroups of
patients meeting TA314 criteria were similar to those in subgroups not
meeting TA314 criteria, depending on the presence of diabetes or
ischaemic aetiology. HF, heart failure; ICD, implantable
cardioverter-deﬁbrillator; SCD, sudden cardiac death.
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limitation is the use of appropriate shocks as a surrogate for
sudden death as the underlying arrhythmia may not have been
subsequently fatal. While this may serve to overestimate the cap-
acity of TA314 to predict risk of SCD, it is reassuring to note
our sensitivity analysis excluding patients with device therapy
reached broadly similar conclusions. Our interpretation of
TA314 guidance for patients with narrow QRS duration was
conservative, although our sensitivity analysis including patients
with narrow QRS arrived at similar conclusions.
CONCLUSION
The recently updated NICE guidelines on ICD implantation can
identify patients with reduced LVEF at increased relative risk of
sudden death. Clinicians should also consider clinical context
and the absolute risk of SCD when advising patients about the
potential risks and beneﬁts of ICD therapy.
Key messages
What is already known on this subject?
▸ Chronic heart failure is associated with increased risk of
sudden death, which can be mitigated by implantable
cardioverter-deﬁbrillators (ICDs).
▸ The National Institute for Health and Care Excellence
suggest that ICD use is cost-effective in selected patients,
outlined in the recently updated TA314 guidance.
What might this study add?
▸ TA314 identiﬁes populations at increased risk of sudden
death.
▸ The performance of TA314 is sensitive to patient context,
including comorbid diabetes and ischaemic heart disease.
How might this impact on clinical practice?
▸ When risk-stratifying individuals according to TA314
guidance on implantable cardioverter-deﬁbrillator use,
clinicians should also consider comorbid diabetes and
ischaemic heart disease.
▸ Future updates to TA314 should consider reﬁning
risk-stratiﬁcation approaches to minimise both preventable
sudden death and overtreatment.
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